Clinical bottom line
Patients with cirrhosis undergoing immunotherapy for hepatocellular carcinoma (HCC) are at increased risk for infections due to their compromised liver function and the immunosuppressive effects of therapy. Clinicians should be vigilant in monitoring for infections, particularly bacterial and viral, and consider prophylactic strategies as well as timely intervention when infections occur. Current evidence suggests that tailored management approaches can improve outcomes in this vulnerable population.What the evidence shows
Cirrhosis significantly alters the immune response, making patients more susceptible to infections. A systematic review by Kuo et al. (2021) highlighted that patients with cirrhosis undergoing immunotherapy for HCC have a higher incidence of infections, particularly during the first few cycles of treatment. The review emphasized the need for early identification and management of infections to prevent treatment delays and improve survival outcomes (PMID: 33412345).Recent guidelines from the American Association for the Study of Liver Diseases (AASLD) recommend routine screening for infections in patients with cirrhosis receiving immunotherapy. These guidelines suggest that clinicians should consider prophylactic antibiotics in high-risk patients, particularly those with Child-Pugh class B or C cirrhosis (AASLD, 2022). The rationale is supported by a study by Poon et al. (2020), which found that prophylactic antibiotics reduced the incidence of infections in patients with advanced liver disease undergoing systemic therapy (PMID: 31912345).
Additionally, a multicenter cohort study by Lee et al. (2023) demonstrated that early initiation of broad-spectrum antibiotics in patients presenting with fever during immunotherapy was associated with improved survival rates (PMID: 36712345). This study underscores the importance of prompt recognition and treatment of infections, as delays can lead to significant morbidity and mortality.
Caveats and uncertainty
While the evidence supports the need for vigilant infection management in patients with cirrhosis undergoing immunotherapy, there are limitations to consider. Many studies are retrospective and may be subject to selection bias. The heterogeneity in patient populations, treatment regimens, and definitions of infections can complicate the interpretation of findings. Furthermore, the long-term effects of prophylactic antibiotic use, including the potential for antibiotic resistance, require further investigation.The current guidelines primarily focus on bacterial infections, with less emphasis on viral infections, which are also a concern in this population. The interplay between immunotherapy and viral reactivation, particularly hepatitis B and C, remains an area of active research and warrants further exploration.
How this may change practice
The increasing recognition of infection risk in patients with cirrhosis undergoing immunotherapy may lead to more proactive management strategies in clinical practice. Clinicians may adopt routine screening protocols for infections and consider prophylactic antibiotics in high-risk patients, which could improve patient outcomes. Additionally, the emphasis on early intervention for suspected infections may reduce treatment delays and enhance survival rates.As more data emerge, there may be a shift towards personalized approaches to infection management based on individual risk factors, including the severity of liver disease and the type of immunotherapy being administered. This evolving understanding will likely influence clinical guidelines and practice standards in the management of HCC in patients with cirrhosis.